House Dust Mite Allergy Market Report 2025

The house dust mite allergy market size has grown rapidly in recent years. It will grow from $2.11 billion in 2024 to $2.39 billion in 2025 at a compound annual growth rate (CAGR) of 13%. The growth in the historic period can be attributed to increased awareness and education, advancements in diagnostic tools, research and clinical studies, healthcare infrastructure development, regulatory guidelines and standards.

The house dust mite allergy market size is expected to see rapid growth in the next few years. It will grow to $4.1 billion in 2029 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to regulatory support and allergen labeling, rising allergy prevalence, telemedicine and remote care, increased focus on precision medicine, expansion of allergen-avoidance products. Major trends in the forecast period include public health awareness campaigns, integration of digital health solutions, focus on indoor environmental quality, growth in immunotherapy solutions, advancements in allergen avoidance products.

The increasing prevalence of asthma is expected to drive the growth of the house dust mite allergy market in the future. Asthma is a condition that causes the airways to narrow, swell, and sometimes produce excess mucus, leading to breathing difficulties. Asthma patients are more susceptible to environmental dust, which can trigger allergic reactions and worsen their condition, resulting in a greater need for anti-allergic medications. Consequently, the rising prevalence of asthma increases the demand for treatments targeting house dust mite allergies. For example, in September 2024, the Asthma and Allergy Foundation of America, a US-based community organization, reported that approximately 10 people die from asthma each day in the U.S., accounting for 3,235 deaths in 2022. Many of these deaths could be prevented with appropriate care and treatment. Therefore, the prevalence of asthma is fueling the demand for house dust mite allergy treatments.

The rise in healthcare expenditure is expected to drive the growth of the house dust mite allergy market in the future. Increased healthcare spending enhances access to medical services, promotes advancements in diagnostic technologies, funds research and development, supports the creation of targeted therapies, expands the availability of allergy management products, improves health insurance coverage, and encourages government initiatives to tackle allergy-related issues. For example, in December 2023, the Centers for Medicare & Medicaid Services, a US-based federal agency, reported that U.S. healthcare spending in 2022 increased by 4.1%, reaching $4.5 trillion, exceeding the 3.2% growth seen in 2021. As a result, the growing healthcare expenditure is contributing to the expansion of the house dust mite allergy market.

The growth of the house dust mite allergy market is expected to be fueled by the increase in urbanization. Urbanization, marked by the expansion of cities and migration from rural to urban areas, creates conditions favorable for the proliferation of microscopic allergens such as dust mites. The trend of escalating urbanization, coupled with growing awareness of indoor allergens and their health impact, is projected to drive demand for diagnostic tools, treatments, and preventive measures related to house dust mite allergies. For instance, as of April 2022, more than 4.3 billion people, constituting 55% of the world’s population, lived in urban settings, and this number is expected to rise to 80% by 2050, as reported by the World Economic Forum. Thus, increasing urbanization is a key factor contributing to the growth of the house dust mite allergy market.

Major companies in the house dust mite allergy market are concentrating on developing innovative solutions, such as sublingual tablets aimed at treating house dust mite allergies, to tackle the rising prevalence of these allergies. A sublingual tablet for treating house dust mite allergies is a form of immunotherapy where a tablet is placed under the tongue, allowing it to dissolve and release small doses of the allergen that triggers the allergy. For example, in January 2023, ALK-Abelló A/S, a pharmaceutical company based in Denmark, received FDA approval for ODACTRA, a sublingual tablet designed for adolescents aged 12 to 17, thereby expanding its previous indication for adults. This approval meets a critical need, as nearly 50% of allergy sufferers are sensitive to house dust mites. Clinical trials showed that ODACTRA effectively alleviated allergy symptoms and had a safety profile comparable to that seen in adults. Although the treatment is generally well-tolerated, patients are advised to keep auto-injectable epinephrine available due to the risk of severe allergic reactions.

Major companies in the house dust mite allergy market are leveraging AI-powered allergy testing to gain a competitive edge. Allergy testing evaluates an individual's immune response to specific allergens. Metropolis Healthcare, in May 2023, launched a 4th generation allergy testing technology based on Component Resolved Diagnostics (CRD) and powered by artificial intelligence. This innovative testing platform assists clinicians in making informed decisions and offers insights into personalized treatment courses for allergic diseases. The technology, utilizing a Nanotechnology-based Multiplex system, enables the detection of specific IgE antibodies against 295 different allergens through a simple blood test, enhancing the precision of allergy-related diagnostic services.

Major companies operating in the house dust mite allergy market include Allergy Therapeutics Plc, Bayer AG, Catalent Inc., GSK Plc, Merz Pharma GmbH & Co KGaA, Sanofi S A, Shionogi & Co. Ltd., Stallergenes Greer International AG, Merck & Co. Inc., Torii Pharmaceutical Co. Ltd., Ergomed PLC, DMS Group, HAL Allergy Group, Trio Lifescience Private Limited, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Johnson and Johnson Inc., Circassia Pharmaceuticals Plc, Biomay Ag, GlaxoSmithKline.

North America was the largest region in the house dust mite allergy market in 2024. Asia-pacific is expected to be the fastest-growing region in the house dust mite allergy market report during the forecast period. The regions covered in the house dust mite allergy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the house dust mite allergy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

House dust mite allergy refers to an allergic reaction triggered by small insects commonly found in household dust. This encompasses the treatment methods employed to address allergic responses such as sneezing and other allergy-related conditions.

The primary product types for managing house dust mite allergy include tablets, nasal drops, and injectables. Tablets represent a compact, solid-dose form that may contain medications with or without excipients. Treatment modalities encompass medication, immunotherapy, nasal irrigation, and other approaches. Diagnosis involves methods such as the skin prick test (SPT) and specific immunoglobulin E (IgE) blood test, among others, utilizing various dosage forms such as solid and liquid. These products find application across diverse end-users, including hospitals, homecare settings, specialty clinics, and others.

The house dust mite allergy market research report is one of a series of new reports that provides house dust mite allergy market statistics, including house dust mite allergy industry global market size, regional shares, competitors with a house dust mite allergy market share, detailed house dust mite allergy market segments, market trends and opportunities and any further data you may need to thrive in the house dust mite allergy industry. This house dust mite allergy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The house dust mite allergy market consists of sales of prescription drugs and over-the-counter drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.